FIELD: pharmaceuticals.
SUBSTANCE: present invention relates to fused tricyclic heterocyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions based thereon and use for HIV integrase inhibition.
EFFECT: obtaining new compounds capable of inhibiting HIV integrase.
15 cl, 4 tbl, 35 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | 2017 |
|
RU2749043C2 |
| PHARMACEUTICALLY ACTIVE DERIVATIVES OF PYRAZOLOTRIAZINE AND/OR PYRAZOLOPYRIMIDINE | 2019 |
|
RU2818563C2 |
| PHOSPHOINDOLES AS HIV INHIBITORS | 2005 |
|
RU2393163C2 |
| CONDENSED HETEROARYLS AND THEIR APPLICATION | 2011 |
|
RU2552114C2 |
| BIARYL DERIVATIVE, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL APPLICATION THEREOF | 2019 |
|
RU2768830C2 |
| CYCLOPROPYLAMIDE DERIVATIVES AS N-HISTAMINE RECEPTOR MODULATORS | 2007 |
|
RU2449989C2 |
| N2-(2-PHENYL)-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND USE THEREOF AS MPS1 INHIBITOR | 2015 |
|
RU2693460C2 |
| MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | 2014 |
|
RU2678327C2 |
| PYRAZOLOTRIAZINE AND/OR PYRAZOLOPYRIMIDINE DERIVATIVES AS A SELECTIVE CYCLIN-DEPENDENT KINASE INHIBITOR | 2019 |
|
RU2809779C2 |
| FGFR INHIBITOR, METHOD FOR PRODUCTION AND APPLICATION THEREOF | 2019 |
|
RU2771526C1 |
